Herceptin-conjugated GQDs loaded with DOX have been prepared for the treatment of HER2-positive breast cancer and can simultaneously deliver herceptin and DOX, taking advantage of the specific targeting effects of herceptin, and these GQDs exert a synergistically enhanced antitumor effect [127]. Here, ERBB2 is linked to breast cancer.